Skip to main content
. 2023 May 2;44(25):2277–2291. doi: 10.1093/eurheartj/ehad197

Figure 3.

Figure 3

Response to statin, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors is dependent on the degree of residual low-density lipoprotein receptor activity; however, for lomitapide, angiopoietin-like protein 3 (ANGPLT3)-directed therapy and lipoprotein apheresis, response is independent of low-density lipoprotein receptor function. Reproduced with permission from Mohamed et al.44.